177734-79-1

Basic information

• Product Name: benzofuran-4-yl trifluoromethanesulfonate
• Synonyms: benzofuran-4-yl trifluoromethanesulfonate;4-(Trifluoromethylsulfonyloxy)benzofuran;Trifluoromethanesulfonic acid benzofuran-4-yl ester;1-benzofuran-4-yl trifluoroMethanesulfonate
• CAS NO: 177734-79-1
• Molecular Formula: C₉H₅F₃O₄S
• Molecular Weight: 266
• Mol File: 177734-79-1.mol

Chemical Properties

• Appearance: /
• Density: 1.586
• CAS DataBase Reference: benzofuran-4-yl trifluoromethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: benzofuran-4-yl trifluoromethanesulfonate(177734-79-1)
• EPA Substance Registry System: benzofuran-4-yl trifluoromethanesulfonate(177734-79-1)

Safety Data

• Hazardous Substances Data: 177734-79-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzofuran-4-yl trifluoromethanesulfonate is used as a synthetic reagent for the preparation of pharmaceuticals. Its ability to form various types of chemical bonds makes it a valuable tool in the synthesis of diverse chemical compounds, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Synthesis:
In the agrochemical industry, benzofuran-4-yl trifluoromethanesulfonate is used as a synthetic reagent for the preparation of agrochemicals. Its versatility in forming different types of chemical bonds enables the synthesis of a wide range of agrochemicals, including pesticides and herbicides, to improve crop protection and yield.
Used in Materials Science:
Benzofuran-4-yl trifluoromethanesulfonate is also used in materials science as a synthetic reagent for the preparation of various materials. Its ability to form carbon-carbon, carbon-nitrogen, and carbon-oxygen bonds allows for the synthesis of materials with unique properties, such as high thermal stability, electrical conductivity, or specific optical characteristics, which can be applied in various fields, including electronics, energy storage, and photonics.

Upstream product

• 480-97-7 4-hydroxybenzofuran 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 112678-09-8 3-carboxy-4-hydroxybenzo-(b)-furan 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 95333-15-6 4-acetylbenzofuran 
• 166599-84-4 benzofuran-4-carboxylic acid 

Relevant articles and documents

Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles

Replacing the naphthalene C-unit of the anti-tuberculosis drug bedaquiline with a range of bicyclic heterocycles of widely differing lipophilicity gave analogs with a 4.5-fold range in clogP values. The biological results for these compounds indicate on average a lower clogP limit of about 5.0 in this series for retention of potent inhibitory activity (MIC90s) against M.tb in culture. Some of the compounds also showed a significant reduction in inhibition of hERG channel potassium current compared with bedaquiline, but there was no common structural feature that distinguished these.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS

Novel tricyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.